Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS Compared to Placebo in Patients with Localised RCC at High Risk of Recurrence After Nephrectomy
Findings from part A of the CheckMate 914 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Sotorasib Shows Increase in PFS and a More Favourable Safety Compared with Docetaxel in Patients with Previously Treated Advanced KRASG12C-mutated NSCLC
Findings from the CodeBreaK 200 study
FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
Efficacy for the regular approval was evaluated in GARNET study
Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients with Small Peripheral NSCLC and Pathologically Confirmed Node-Negative Disease
Findings from the CALGB 140503 study
A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response Association of Colorectal Cancer Risk with Subdiaphragmatic Radiotherapy
The first study to demonstrate an association between therapeutic radiation dose to the large bowel and colorectal cancer
FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer
Evidence for efficacy is based on the results from the TROPiCS-02 study
First-Line Serplulimab in Combination with Chemotherapy Improves Survival in Patients with PD-L1-positive, Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma
Findings from the ASTRUM-007 study
Final DFS Analysis Demonstrates that Adjuvant Osimertinib Improves DFS in Patients with Resected EGFR-mutated Stage IB-IIIA NSCLC
Updated disease-free survival data at the protocol-specified maturity of the ADAURA study
FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Evidence for efficacy is based on the results from the BRUIN study
Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast Cancer Highlight Priority Molecular Targets for Future Clinical Trials
Genomic features of HRD, PIK3CA mutations with copy number amplifications, and copy number amplifications are enriched in young women
Prospective Evaluation of Benefit in Patients with Advanced Cancer Treated with ctDNA Matched Therapy as Recommended by a Molecular Tumour Board
Findings from the genomic profiling of ctDNA in patients included in the STING precision medicine study
FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer
FDA also approved the Guardant360 CDx assay as a companion diagnostic